PerkinElmer Expands its OneSource® Laboratory Services with Acquisition of LabMetrix Technologies
News Apr 01, 2008
PerkinElmer, Inc. has announced the acquisition of LabMetrix Technologies, the largest independent provider of metrology-based multi-vendor analytical instrument qualification solutions.
The acquisition of LabMetrix adds technology, tools, proven processes and compliance expertise to PerkinElmer’s suite of OneSource® laboratory services, strengthening its support of customers in a wide range of industries including pharmaceutical, medical device, food, toy and other consumer goods. The terms of the deal were not disclosed.
“This acquisition expands our support of customers in regulated markets by combining metrology-based multi-vendor qualification solutions with PerkinElmer’s existing services capabilities,” said Robert F. Friel, president and chief executive officer, PerkinElmer.
“With the addition of LabMetrix’s technology-assisted compliance solution, we can provide customers with the most robust qualification environment available for a broad range of instruments and technologies in their labs, regardless of manufacturer.”
Greater public attention on product safety coupled with customers’ increased need for improved scientific output continue to drive greater demand for comprehensive regulatory compliance solutions.
According to PerkinElmer, the combination of LabMetrix’s technology solutions with its existing OneSource offerings will make it easier for customers to demonstrate the accuracy of their analytical measurements while helping drive down the cost of compliance through automation, standardization and streamlined documentation. LabMetrix generated revenues of approximately $5 million in 2007.
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE